期刊文献+

冠心病患者血清可溶性OX40配体和CRP水平的临床意义 被引量:1

Clinical Significance of Serum Soluble OX40 Ligand and C Reactive Protein Levels in Patients with Coronary Heart Disease
原文传递
导出
摘要 目的探讨不同类型冠心病患者血清可溶性OX40配体(sOX40L)和C反应蛋白(Creactive protein,CRP)水平的临床意义。方法分别采用ELISA法和免疫透射比浊法检测458例疑似或诊断为冠心病患者血清sOX40L和CRP的浓度,采用冠脉造影术和ACC/AHA评分法判定冠状动脉病变程度。结果急性冠脉综合征(ACS)组患者血清sOX40L和CRP水平及冠脉评分均明显高于稳定型心绞痛(SAP)组和正常对照(CT)组(P<0.01);sOX40L与CRP及冠脉评分均呈正相关(P<0.01),CRP与冠脉评分亦呈正相关(P<0.01)。结论血清sOX40L和CRP水平与冠心病患者的病情严重程度及冠状动脉病变程度密切相关,sOX40L有望与CRP一样,作为炎症指标预测冠心病的发生和预后。 Objective To study the clinical significance of serum soluble OX40 ligand (sOX40L)and C reactive protein (CRP)levels in the patients with coronary heart disease (CAD). Methods The serum sOX40L and CRP concentrations of 458 patients or suspected patients with CAD were determined by ELISA and immunoturbidimetric method respectively. The severity of coronary artery lesion was evaluated according to coronary angiography and ACC / AHA coronary scoring system. Results The serum sOX40L and CRP levels as well as coronary scoring were significantly higher in acute coronary syndrome (ACS)group than in stable angina(SAP)and normal control(CT)groups(P 0. 01). The sOX40L level was positively related to the CRP level and coronary score(P 0. 01), and the CRP level was also positively related to the coronary score(P 0. 01). Conclusion The serum sOX40L and CRP levels were closely related to the severities of CAD and coronary artery lesion. Like CRP, sOX40L might also be used as an marker of inflammation for prediction of onset and prognosis of CAD.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第10期1116-1119,共4页 Chinese Journal of Biologicals
基金 重庆医科大学基金资助(XBYB2008019)
关键词 冠心病 冠脉造影术 OX40配体 C反应蛋白 Coronary heart disease(CAD) Coronary angiography OX40 ligand Creactive protein
  • 相关文献

参考文献13

  • 1Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis( * ) [ J ]. Annu Rev Immunol, 2009, 27 (4): 165-197.
  • 2Mendel I,Shevach EM. Activated T cells express the OX40 ligand:requirements for induction and costimulatory function [J]. Immunology, 2006, 117(2): 196-204.
  • 3Wang X, Ria M, Kelmenson PM, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility [J]. Nat Genet, 2005, 37 (4): 365- 372.
  • 4Lizardi-Cervera J, Chavez-Tapia NC, Perez-Bautista O, et al. Association among C-reactive protein, fatty liver disease, and cardiovascular risk [J]. Dig Dis Sci, 2007, 52(9): 2375-2379.
  • 5Lowe GD. The association between elevated levels of inflammation biomarkers and coronary artery disease and death [J]. CMAJ, 2006, 174(4): 479-480.
  • 6Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underly- ing the ACC/AHA clinical practice guidelines [J].JAMA, 2009, 301(8): 831-841.
  • 7Sugamura K,Ishii N,Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 [J]. Nat Rev Immunol, 2004, 4 (6): 420-431.
  • 8Paigen B, Mitchell D, Reue K, et al. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoeprotein levels in mice [J]. Proc Natl Acad Sci USA, 1987, 84 (11): 3763-3767.
  • 9Ria M, Eriksson P, Boquist S, et ol. Human genetic evidence that OX40 is implicated in myocardial infarction [J]. Biochem Biophys Res Commun, 2006, 339(3): 1001-1006.
  • 10Shankar A, Li J, Nieto FJ, et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovaseular disease, diabetes, or hypertension [J]. Am Heart J, 2007, 154 (3): 495-501.

同被引文献12

  • 1Zhang NN, Andresen BT, Zhang CH, et al. Inflammation anti reactive oxygen species in cardiovascular disease [J]. World J Cardiol, 2010, 2(12): 408-410.
  • 2Liu H, Zhao D, Ma CS, et al. C-reactive protein predicts the severily of coronary artery disease beyond low-density lipoprotein cholesterol [J ]. Angiology, 2012, 63 (3) : 218-222.
  • 3Wang Q, Zhu X, Xu Q, et al. Effect of C-reactive protein on gene expression in vascular endothelial cells [J]. Am J Physiol Heart Circ Physiol, 2005, 288 (4): H1539-H1545.
  • 4Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events [ J ]. Semin Immunopathol, 2009,31( 1 ) : 79-94.
  • 5Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age [J]. Nat Clin Pract Cardiovasc Med, 2005, 2 (1):29-36.
  • 6Scirica BM, Morrow DA. Is C-reactive protein an innocent by- stander or proatherogenic culprit? The verdict is still out [J]. Circulation, 2006,113 ( 17 ) : 2128-2134, 2151.
  • 7Puccetti L, Pasqui AL, Bruni F, et ol. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment [J].Int J Cardiol, 2007, 119 (1): 41-47.
  • 8Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial ceUs: implications for clinical and subclinical atherosclerosis [J]. J Am Coll Cardiol,2006,47 (7) : 1369-1378.
  • 9Li L, Roumeliotis N, Sawamura T, et al. C-Reactive protein en- hances LOX-1 expression in human aortic endothelial cells rele- vance of LOX-1 to C-reactive protein-induced endothelial dys- function [J]. Circ Res, 2004, 95 (9): 877-883.
  • 10Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma [J]. Circulation, 1996, 94 (6): 1226-1232.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部